The Brazilian legislation did not recognize pharmaceutical patents for products and processes up until 1996, an exemption which started in 1945 for products and 1969, for processes. In this period, the domestic companies freely reproduced medicines developed by large companies from abroad and...

There is an emerging body of literature that examines how pro-poor innovations should be created and what business models should accompany them. However, there is little on actual implementation practises and the present paper attempts to fill this void by analyzing the findings of the...